ConductScience.org, home

Paper41333481

Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment.

Dong Q and 3 others. Front Immunol, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment. Papers, record 41333481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41333481

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment.
PubMed
Journal
Front Immunol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-12-05
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dong QQinyi
2Zhang ZZijian
3Li SSiying
4Liang LLili

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Tumor MicroenvironmentMajor topic
Skin NeoplasmsMajor topic
ImmunotherapyMajor topic
Carcinoma, Squamous CellMajor topic
Humans
Immune Checkpoint Inhibitors
Animals

Source PubMed

Download CSV of topics

References140

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132849616Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment.Front Immunol2020https://conductscience.org/library/papers/32849616PubMed
226811634Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.World J Gastroenterol2016https://conductscience.org/library/papers/26811634PubMed
322566933Molecular mechanisms of treg-mediated T cell suppression.Front Immunol2012https://conductscience.org/library/papers/22566933PubMed
437686588Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre.Cancers (Basel)2023https://conductscience.org/library/papers/37686588PubMed
536148955Single-cell analysis reveals that cancer-associated fibroblasts stimulate oral squamous cell carcinoma invasion via the TGF-β/Smad pathway.Acta Biochim Biophys Sin (Shanghai)2022https://conductscience.org/library/papers/36148955PubMed
631091995Survival Outcomes for Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck.Ann Otol Rhinol Laryngol2019https://conductscience.org/library/papers/31091995PubMed
733989559Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.Lancet Oncol2021https://conductscience.org/library/papers/33989559PubMed
839912096Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations.Cancer Manag Res2025https://conductscience.org/library/papers/39912096PubMed
926946344Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice.Gastroenterology2016https://conductscience.org/library/papers/26946344PubMed
1038280470VEGF signaling: Role in angiogenesis and beyond.Biochim Biophys Acta Rev Cancer2024https://conductscience.org/library/papers/38280470PubMed
1139663166
Prediction of relative survival trends in patients with cutaneous squamous cell carcinoma using a model-based period analysis: a retrospective analysis of the surveillance, epidemiology, and end results database.
BMJ Open2024https://conductscience.org/library/papers/39663166PubMed
1228813164Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.J Clin Oncol2017https://conductscience.org/library/papers/28813164PubMed
1326216631Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.Adv Cancer Res2015https://conductscience.org/library/papers/26216631PubMed
1434375482Tumor-associated macrophage-derived transforming growth factor-β promotes colorectal cancer progression through HIF1-TRIB3 signaling.Cancer Sci2021https://conductscience.org/library/papers/34375482PubMed
1534224993TIM-3: An update on immunotherapy.Int Immunopharmacol2021https://conductscience.org/library/papers/34224993PubMed
1637492477Association between pH regulation of the tumor microenvironment and immunological state.Front Oncol2023https://conductscience.org/library/papers/37492477PubMed
1732158481Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.Drugs Context2019https://conductscience.org/library/papers/32158481PubMed
1835406451Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.Cancers (Basel)2022https://conductscience.org/library/papers/35406451PubMed
1934409048New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review.Front Med (Lausanne)2021https://conductscience.org/library/papers/34409048PubMed
2037146405Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease.EBioMedicine2023https://conductscience.org/library/papers/37146405PubMed

See all 140 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42795027Treatment Strategies for Advanced Cutaneous Squamous Cell Carcinoma Following Anti-PD-1 Immunotherapy Failure: A Systematic Review of the Literature and Ongoing Trials.Cancers (Basel)2026https://conductscience.org/library/papers/42795027PubMed
42609920Single-cell transcriptomic analysis of cutaneous squamous cell carcinoma identifies an NR1H3-associated angiogenic macrophage state.Front Immunol2026https://conductscience.org/library/papers/42609920PubMed
42088400Recent Advances in Novel Drug Delivery Systems for the Management of Cutaneous Squamous Cell Carcinoma.Int J Nanomedicine2026https://conductscience.org/library/papers/42088400PubMed
41514652Spontaneous cSCC Murine Model Shows Limited Response to PD-1 Blockade and Radiation Combination Therapy.Cancers (Basel)2025https://conductscience.org/library/papers/41514652PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
TGFB17040PubTator's text mininghttps://conductscience.org/library/genes/7040NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41333481

GET https://conductscience.org/api/papers/v1/41333481/references?page=2